Related Experiment Video
Updated: Dec 21, 2025
A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
Bone-Targeting AAV-Mediated Gene Silencing in Osteoclasts for Osteoporosis Therapy
Yeon-Suk Yang1, Jun Xie2,3,4, Sachin Chaugule1
1Division of Rheumatology, University of Massachusetts Medical School, Worcester, MA, USA.
Abstract:
Improper activity of bone-resorbing osteoclasts results in low bone density and deterioration of bone structure, which increase the risk of fractures. Anti-resorptive therapies targeting osteoclasts have proven effective in preserving bone mass, but these therapeutic agents lead to defective new bone formation and numerous potential side effects. In this study, we demonstrate that recombinant adeno-associated virus, serotype 9 (rAAV9) can deliver to osteoclasts an artificial microRNA (amiR) that silences expression of key osteoclast regulators, RANK (receptor activator for nuclear factor κB) and cathepsin K (rAAV9.amiR-rank, rAAV9.amiR-ctsk), to prevent bone loss in osteoporosis. As rAAV9 is highly effective for the transduction of osteoclasts, systemic administration of rAAV9 carrying amiR-rank or amiR-ctsk results in a significant increase of bone mass in mice. Furthermore, the bone-targeting peptide motif (Asp)14 or (AspSerSer)6 was grafted onto the AAV9-VP2 capsid protein, resulting in significant reduction of transgene expression in non-bone peripheral organs. Finally, systemic delivery of bone-targeting rAAV9.amiR-ctsk counteracts bone loss and improves bone mechanical properties in mouse models of postmenopausal and senile osteoporosis. Collectively, inhibition of osteoclast-mediated bone resorption via bone-targeting rAAV9-mediated silencing of ctsk is a promising gene therapy that can preserve bone formation and mitigate osteoporosis, while limiting adverse off-target effects.
Insights
Gene therapy using bone-targeting recombinant adeno-associated virus serotype 9 (rAAV9) effectively silences osteoclast regulators, preventing bone loss in osteoporosis models. This approach enhances bone mass and mechanical properties while minimizing side effects.
Area of Science:
- Gene Therapy
- Molecular Biology
- Orthopedics
Background:
- Osteoclast dysfunction causes low bone density and fracture risk, characteristic of osteoporosis.
- Current anti-resorptive therapies for osteoporosis improve bone mass but impair new bone formation and cause side effects.
- Targeting key osteoclast regulators offers a potential therapeutic strategy for osteoporosis.
Purpose of the Study:
- To develop a gene therapy using recombinant adeno-associated virus serotype 9 (rAAV9) to deliver artificial microRNAs (amiRs) targeting osteoclast regulators RANK and cathepsin K.
- To engineer rAAV9 with bone-targeting peptides to enhance delivery to osteoclasts and reduce off-target effects in peripheral organs.
- To evaluate the efficacy of bone-targeting rAAV9-mediated gene silencing in preventing bone loss and improving bone quality in osteoporosis models.
Main Methods:
- Systemic administration of rAAV9 vectors carrying amiRs targeting RANK (rAAV9.amiR-rank) or cathepsin K (rAAV9.amiR-ctsk) in mouse models.
- Grafting bone-targeting peptide motifs (Asp)14 or (AspSerSer)6 onto the AAV9-VP2 capsid protein.
- Assessing bone mass, bone structure, and mechanical properties in treated mice, alongside transgene expression analysis in various organs.
Main Results:
- Systemic delivery of rAAV9.amiR-rank or rAAV9.amiR-ctsk significantly increased bone mass in mice.
- Bone-targeting modifications reduced transgene expression in non-bone peripheral organs.
- Systemic delivery of bone-targeting rAAV9.amiR-ctsk counteracted bone loss and improved bone mechanical properties in postmenopausal and senile osteoporosis models.
Conclusions:
- Inhibition of osteoclast-mediated bone resorption via rAAV9-mediated silencing of cathepsin K is a promising gene therapy for osteoporosis.
- Bone-targeting rAAV9 delivery preserves bone formation and mitigates osteoporosis progression.
- This approach effectively limits adverse off-target effects, offering a safer therapeutic strategy.
